Regulation of peroxisome proliferator-activated receptor-α expression during lung inflammation

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 2, 2008, Pages 324-330

  Becker, Julien ^a   Delayre Orthez, Carine ^a   Frossard, Nelly ^a   Pons, Françoise ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Acute lung injury; Asthma; Dexamethasone; Fenofibrate; Inflammation; Lipopolysaccharide; Lung; Mouse; PPAR ; Tumor necrosis factor

Indexed keywords

DEXAMETHASONE; FENOFIBRATE; GLUCOCORTICOID; LIPOPOLYSACCHARIDE; MESSENGER RNA; OVALBUMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DEXAMETHASONE; DOWN-REGULATION; GLUCOCORTICOIDS; HYPERSENSITIVITY; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; PPAR ALPHA; PROCETOFEN; RESPIRATORY DISTRESS SYNDROME, ADULT; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40049100693     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.08.001     Document Type: Article

References (26)

1. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
2. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 65 (2003) 261-311
3. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
4. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Murakami A., et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61 (2001) 2424-2428
5. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277 (2002) 48051-48057
6. Sheu M.Y., Fowler A.J., Kao J., Schmuth M., Schoonjans K., Auwerx J., et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118 (2002) 94-101
7. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., and Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) 323-330
8. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 36 (1998) 345-349
9. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
10. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 (2003) 672-688
11. Belvisi M.G., Hele D.J., and Birrell M.A. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets 8 (2004) 265-285
12. Delayre-Orthez C., Becker J., Guenon I., Lagente V., Auwerx J., Frossard N., et al. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 6 (2005) 91-101
13. Trifilieff A., Bench A., Hanley M., Bayley D., Campbell E., and Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF- kappaB-independent effect. Br J Pharmacol 139 (2003) 163-171
14. Delayre-Orthez C., Becker J., Auwerx J., Frossard N., and Pons F. PPARalpha decreases airway inflammation associated with asthma in the mouse. Fundam Clin Pharmacol 18 (2004) 220
15. Becker J., Delayre-Orthez C., Frossard N., and Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fundam Clin Pharmacol 20 (2006) 429-447
16. Lemberger T., Staels B., Saladin R., Desvergne B., Auwerx J., and Wahli W. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J Biol Chem 269 (1994) 24527-24530
17. Lemberger T., Saladin R., Vazquez M., Assimacopoulos F., Staels B., Desvergne B., et al. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 271 (1996) 1764-1769
18. Beier K., Volkl A., and Fahimi H.D. TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver. FEBS Lett 412 (1997) 385-387
19. Parmentier J.H., Schohn H., Bronner M., Ferrari L., Batt A.M., Dauca M., et al. Regulation of CYP4A1 and peroxisome proliferator-activated receptor alpha expression by interleukin-1beta, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes. Biochem Pharmacol 54 (1997) 889-898
20. Tai E.S., bin Ali A., Zhang Q., Loh L.M., Tan C.E., Retnam L., et al. Hepatic expression of PPARalpha, a molecular target of fibrates, is regulated during inflammation in a gender-specific manner. FEBS Lett 546 (2003) 237-240
21. Delayre-Orthez C., de Blay F., Frossard N., and Pons F. Dose-dependent effects of endotoxins on allergen sensitization and challenge in the mouse. Clin Exp Allergy 34 (2004) 1789-1795
22. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
23. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., and Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53 (1998) 14-22
24. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., and Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142 (2001) 4195-4202
25. Reynders V., Loitsch S., Steinhauer C., Wagner T., Steinhilber D., and Bargon J. Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res 7 (2006) 104-118
26. Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, et al. Expression and content of PPARs is reduced in skeletal muscle of COPD patients. Eur Respir J 2007.